Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.

Blood - 24 Mar 2016

Luskin Marlise R, Lee Ju-Whei, Fernandez Hugo F, Abdel-Wahab Omar, Bennett John M, Ketterling Rhett P, Lazarus Hillard M, Levine Ross L, Litzow Mark R, Paietta Elisabeth M, Patel Jay P, Racevskis Janis, Rowe Jacob M, Tallman Martin S, Sun Zhuoxin, Luger Selina M

Abstract excerpt

The initial report of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m(2)) improved overall survival in adults <60 years old with acute myeloid leukemia (AML); however, at initial analysis, the benefit was restricted to younger patients (<50 years) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Cytogenetics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Daunorubicin

Share to DNA (Cytosine-5-)-Methyltransferases

Share to DNA Methyltransferase 3A

Share to fms-Like Tyrosine Kinase 3

Share to Induction Chemotherapy

Share to Nucleophosmin

Source

Open in PubMed Open full text

Identifiers

PMID: 26755712
DOI: 10.1182/blood-2015-07-657403
PMCID: PMC4807422

Genes

NPM1
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.PMID 26755712Read ↗

Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.Semantic proximity Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Updates on targeted therapies for acute myeloid leukaemia.Semantic proximity Read ↗

Frontline treatment of AML in adults.Semantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

The clinical impact of the molecular landscape of acute myeloid leukemiaSemantic proximity Read ↗

Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities.Semantic proximity Read ↗

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.Semantic proximity Read ↗

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxSemantic proximity Read ↗

Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias.Semantic proximity Read ↗

Anthracycline dose intensification in acute myeloid leukemia.Semantic proximity Read ↗

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.